To determine whether the aberrant increase of NRASG12D expression levels observed in our cells treated with the combination of MKC‐8866 and BEZ235 is mediated through stabilizing NRAS mRNA, we pretreated pre‐B NRASG12D ALL cells with either MKC‐8866 or BEZ235 as single agents, followed by actinomycin D treatment to inhibit RNA transcription. Here, NRAS is linked to acute lymphoblastic leukemia.